Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Thoracic Medicine and Surgery, Temple University Medical School, Philadelphia, Pennsylvania, USA.
BMJ Open Respir Res. 2020 Feb;7(1). doi: 10.1136/bmjresp-2018-000392.
Quercetin is a plant flavonoid and has potent antioxidant and anti-inflammatory properties. In a preclinical model of chronic obstructive pulmonary disease (COPD), quercetin reduced markers of both oxidative stress and lung inflammation and also reduced rhinovirus-induced progression of lung disease. Although quercetin appears to be an attractive natural alternative to manage COPD, the safety of quercetin supplementation in this population is unknown.
We recruited COPD patients with mild-to-severe lung disease with FVE1 ranging between >35% and <80% and supplemented with either placebo or quercetin at 500, 1000 or 2000 mg/day in a dose-escalation manner. The duration of quercetin supplementation was 1 week.
Patients had no study drug-related severe adverse events based on blood tests, which included both complete blood counts and evaluation of comprehensive metabolic panel. One of the patients reported mild adverse events included gastro-oesophageal reflux disease, which was observed in both placebo and quercetin groups.
Quercetin was safely tolerated up to 2000 mg/day as assessed by lung function, blood profile and COPD assessment test questionnaire.
NCT01708278.
槲皮素是一种植物类黄酮，具有很强的抗氧化和抗炎特性。在慢性阻塞性肺疾病（COPD）的临床前模型中，槲皮素降低了氧化应激和肺部炎症的标志物，还降低了鼻病毒引起的肺部疾病进展。虽然槲皮素似乎是一种有吸引力的天然替代品，可以用于治疗 COPD，但这种人群补充槲皮素的安全性尚不清楚。
我们招募了 FVE1 为 35%至 80%之间的轻至重度肺疾病的 COPD 患者，以剂量递增的方式分别给予安慰剂或槲皮素 500、1000 或 2000mg/天。槲皮素的补充持续时间为 1 周。
根据血液测试，包括全血细胞计数和全面代谢面板评估，患者没有与研究药物相关的严重不良事件。一名患者报告了轻度不良事件，包括胃食管反流病，在安慰剂和槲皮素组均观察到。
通过肺功能、血液检查和 COPD 评估测试问卷评估，槲皮素最高耐受剂量可达 2000mg/天。
NCT01708278。
